Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106167 · ClinicalTrials.gov registry record
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
A clinical trial, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04106167 is a clinical trial that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT04106167 was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Interventions
- GENETIC Allogeneic natural killer (NK) cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2023-08-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04106167
The ClinicalTrials.gov registry entry for NCT04106167 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic natural killer (NK) cell is the first listed.
NCT04106167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04106167 about?
NCT04106167 is a clinical study titled "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy". Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this stu...
What is the current status of trial NCT04106167?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2019-06-11. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT04106167?
The interventions under investigation include: Allogeneic natural killer (NK) cell (GENETIC).
Who is sponsoring clinical trial NCT04106167?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.